Evidence map›Paper›PMID 42042522›Full record

ArticleJournal of imaging2026

Automated Morphological Profiling via Deep Learning-Based Segmentation for High-Throughput Phenotypic Screening.

Bendegúz H Zováthi, Philipp Kainz

Abstract read
In one paragraph

Article in Journal of imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bendegúz H ZováthiFaculty of Information Technology and Bionics, Pázmány Péter Catholic University, 1083 Budapest, Hungary.ORCID 0000-0003-4298-635X
Philipp KainzKOLAIDO GmbH, Flughafenstrasse 11, 9423 Thal, Switzerland.ORCID 0000-0001-7970-370X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reproducible morphological profiling, particularly for drug discovery, has become an important tool for compound evaluation. Established workflows such as CellProfiler provide a widely adopted foundation for Cell Painting analysis. However, conventional pipelines often require substantial manual configuration and technical expertise, which can limit scalability and accessibility. In this study, a fully automated deep learning-based workflow is presented for segmentation-driven morphological profiling from raw microscopy data. Using a curated subset of the JUMP Cell Painting pilot dataset, ground-truth masks were generated and used to train a U-net-based segmentation model in the IKOSA platform. Post-processing strategies were introduced to improve instance separation and reduce segmentation artifacts. The final model achieved strong segmentation performance (precision/recall/AP up to 0.98/0.94/0.92 for nuclei), with an average runtime of 2.2 s per 1080 × 1080 image. Segmentation outputs enabled large-scale feature extraction, yielding 3664 morphological descriptors that showed high correlation with CellProfiler-derived measurements (normalized MAE: 0.0298). Feature prioritization further reduced redundancy to 1145 informative descriptors. These results demonstrate that automated deep learning pipelines can complement established Cell Painting workflows by reducing configuration overhead while maintaining compatibility with validated morphological profiling standards. The proposed workflow may help improve resource efficiency in drug discovery and personalized medicine.

Indexed as

artificial intelligenceCell Paintingdeep learning segmentationdrug discoveryhigh-content screeninghigh-throughput imaginginstance segmentationmicroscopic image analysismorphological profilingphenotypic screening

Identifiers

PMID42042522
PMCPMC13117058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.